Molecular Mechanisms of Fibrinolysis in Man^[*]

• 

^* Presented at the Sixth International Congress on Thrombosis and Haemostasis, June 1977, Philadelphia, Pennsylvania

• References

• 1 Agarwal KC, Steiner M. 1976; Effect of serotonin on cyclic nucleotides of human platelets. Biochemical and Biophysical Research Communications 69: 962
• 2 Bagdasarian A, Lahiri B, Colman RW. 1972; Origin of the high molecular weight activator of prekallikrein. Journal of Biological Chemistry 248: 7742
• 3 Baja SP, Castellino FJ. 1977; Activation of human plasminogen by equimolar level of streptokinase. Journal of Biological Chemistry 252: 492
• 4 Bettex-Galland M, Luscher EF. 1960; Studies on the metabolism of human blood platelets in relation to clot retraction. Thrombosis et Diathesis Haemorrhagica 4: 178
• 5 Bouma BN, Griffin JH. 1977; Human prekallikrein (plasminogen proactivator). Purification, characterization, and activation by activated factor XII. Thrombosis and Haemostasis 38: 136 (Abst)
• 6 Brockway WJ, Castellino FJ. 1971; The mechanism of the inhibition of plasmin activity by e-aminocaproic acid. Journal of Biological Chemistry 246: 4641
• 7 Bull BS, Zucker MB. 1965; Changes in platelet volume produced by temperature, metabolic inhibitors and aggregating agents. Proc. Soc. Experimental Biology and Medicine 120: 296
• 8 Chao FC, Shepro D, Tullis JL, Belamorich FA, Curby WA. 1976; Similarities between platelet contraction and cellular motility during mitosis. role of platelet microtubules in clot retraction. Journal of Cellular Sciences 20: 569 (10)
• 9 Cochrane CG, Revak SD, Wuepper KD. 1973; Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. Journal of Experimental Medicine 138: 1504 (12)
• 10 Collen D. 1976; Identification and some properties of a new fastreacting plasmin inhibitor in human plasma. European Journal of Biochemistry 69: 209
• 11 Collen D, DeCock F, Verstraete M. 1975; Immunochemical distinction between antiplasmin and α₁-antitrypsin. Thrombosis Research 7: 245
• 12 Collen D, Nauwelaers F, Wiman B. Isolation and partial characterization of antiplasmin, the fast reacting plasmin inhibitor of human plasma. Proceedings of the IIIrd Conference of Chemical Fibrinolysis Thrombolysis. Progress in Fibrinolysis, Glasgow. Sept 29-30 1976. Raven Press; New York: (in press)
• 13 Colman RW, Bagdasarian A, Talamo RC, Seavey M, Scott CF, Kaplan AP. 1975; Williams trait: Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. Journal of Clinical Investigations 56: 1650
• 14 Conley CL. 1960. Platelets in clot retraction. Blood Platelets. Little, Brown; Boston: 437
• 15 Deutsch DG, Mertz ET. 1970; Plasminogen. Purification from human plasma by affinity chromatography. Science 170: 1095
• 16 Donaldson VH, Glueck HI, Miller MA, Movat HZ, Habal FM. 1976; Kininogen deficiency in Fitzgerald trait. Role of high molecular weight kininogen in clotting and fibrinolysis. Journal of Laboratory and Clinical Medicine 87: 327
• 17 Droller MJ. 1973; Ultrastructure of the platelet release response to various aggregating agents and their inhibitors. Laboratory Investigations 29: 595
• 18 Edy J, Collen D. The interaction in human plasma of antiplasmin, the fast-reacting plasmin inhibitor, with plasmin, thrombin, trypsin and chymotrypsin. Biochimica et biophysica acta. in press
• 19 Edy J, Collen D, Verstraete M. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrates S-2251. Proceedings of the IIIrd Conference of Chemical Fibrinolysis Thrombolysis, Progress in Fibrinolysis, Glasgow. Sept 29-30 1976. Raven Press; New York: (in press)
• 20 Edy J, DeCock F, Collen D. 1976; Inhibition of plasmin by normal and antiplasmin depleted human plasma. Thrombosis Research 8: 513
• 21 Fantl P. 1973; Thiol groups of blood platelets in relation to clot retraction. Nature 198: 95
• 22 Fearnley GR, Balmforth G, Fearnley E. 1957; Evidence of diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis. Clinical Science 16: 645
• 23 Fearnley GR, Lackner R. 1955; Fibrinolytic-activity of normal blood. British Journal of Haematology 1: 189
• 24 Fearnley GR, Revill R, Tweed JM. 1952; Observations on the inactivation of fibrinolytic activity in shed blood. Clinical Science 11: 309
• 25 Gallimore MJ. 1967; Effect of diluents on blood clot lysis. Journal of Clinical Pathology 20: 234
• 26 Gallimore MJ, Nulkar MV, Shaw JTB. 1965; A comparative study of the inhibitors of fibrinolysis in human, dog and rabbit blood. Thrombosis et Diathesis Haemorrhagica 14: 145
• 27 Gallimore MJ, Shaw JTB. 1967; Some aspects of fibrin clot lysis and its inhibition by human serum. Thrombosis et Diathesis Haemorrhagica 18: 101
• 28 Griffin JH. 1977; New hypothesis for the molecular mechanism of surface-dependent activation of Hageman Factor. Thrombosis and Haemostasis 38: 50 (Abst)
• 29 Griffin JH, Cochrane CG. 1976; Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proceedings of the National Academy of Sciences USA 73: 2554
• 30 Groskopf WR, Hsieh B, Summaria L, Robbins KC. 1969; Studies in the active center of human plasmin. Journal of Biological Chemistry 244: 369
• 31 Han P, Ardlie NG. 1974; Influence of pH, temperature and calcium on platelet aggregation: Maintenance of environmental pH and platelet function for in vitro studies in plasma stored at 37°C. British Journal of Haematology 26: 373
• 32 Harbury CB, Schrier SL. 1974; Effect of a partial release reaction on subsequent platelet function. Journal of Laboratory and Clinical Medicine 83: 877
• 33 Hardisty RM, Stacey RS. 1955; 5-hydroxytryptamine in normal human platelets. Journal of Physiology 130: 711
• 34 Hartmann RC, Conley CL. 1953; Clot retraction as a measure of platelet function. effects of certain experimental conditions on platelets in vitro. Bulletin of the John Hopkins Hospital 93: 355
• 35 Hedner U, Collen D. 1976; Immunochemical distinction between the inhibitors of plasminogen activation and antiplasmin in human plasma. Thrombosis Research 8: 875
• 36 Holmsen H, Day HJ, Stormorken H. 1969; Blood platelets release reaction. Scandinavian Journal of Haematology Suppl 8 3
• 37 Iatridis SG, Ferguson JH. 1962; Active Hageman Factor. A plasma lysokinase of the human fibrinolytic system. Journal of Clinical Investigation 41: 1277
• 38 Kaplan AP. 1976; The Hageman factor dependent pathways of coagulation, fibrinolysis, and kinin-generation. Seminars in Thrombosis and Haemostosis 3: 1
• 39 Kaplan AP, Austen KF. 1970; A prealbumin activator of prekallikrein. Journal of Immunology 105: 802
• 40 Kaplan AP, Austen KF. 1971; A prealbumin activator of prekallikrein II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. Journal of Experimental Medicine 133: 696
• 41 Kaplan AP, Austen KF. 1972; The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. Journal of Experimental Medicine 136: 1378
• 42 Kaplan AP, Goetzl EJ, Austen KF. 1973; The fibrinolytic pathway of human plasma II. 1973 The generation of chemotactic activity by activation of plasminogen proactivator Journal of Clinical Investigation 52: 2591
• 43 Kattlove HE. 1973; Effect of cold on platelets-III. Adenine nucleotide metabolism after brief storage at cold temperature. Blood 42: 557
• 44 Kletzien RF, Perdue JF, Springer A. 1972; Cytochalasin A & B. inhibition of sugar uptake in cultured cells. Journal of Biological Chemistry 247: 2964
• 45 Laake K, Vennerod AM. 1974; Factor XII induced fibrinolysis. Studies on the separation of prekallikrein, plasminogen proactivator, and factor XII in human plasma. Thrombosis Research 4: 285
• 46 Liu CY, Scott CF, Bagdasarian A, Pierce JV, Kaplan AP, Colman RW. 1977; Potentiation of the function of Hageman factor fragments by high molecular weight kininogen. Journal of Clinical Investigation 60: 7
• 47 Lüscher EF. 1960. Retraction activity of the platelets. biochemical background and physiological significance. Blood Platelets Little, Brown; Boston: 445
• 48 Mandle JrR, Colman RW, Kaplan AP. 1976; Identification of prekallikrein and HMW-kininogen as a circulating complex in human plasma. Proceedings of the National Academy of Sciences USA 73: 4179
• 49 Mandle JrR, Kaplan AP. 1977; a Plasminogen proactivators of human plasma. Relationship to prekallikrein and Factor XI. Federation Proceedings 36: 329 (Abst.)
• 50 Mandle JrR, Kaplan AP. 1977; b Hageman factor substrates. Human plasma prekallikrein. Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. Journal of Biological Chemistry 252: 6097
• 51 Meier HL, Pierce JV, Colman RW, Kaplan AP. 1977; a Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. Journal of Clinical Investigation 60: 18
• 52 Meier HL, Scott CF, Mandle JrR, Webster ME, Pierce JV, Colman RW, Kaplan AP. 1977; b Requirements for contact activation of human Hageman factor. Annals of the New York Academy of Sciences 283: 93
• 53 Meier HL, Thompson RE, Kaplan AP. 1977; c Activation of Hageman factor by factor XIa-HMW-kininogen. Thrombosis and Haemostasis 38: 14 (Abst.)
• 54 Moroi M, Aoki N. 1976; Isolation and characterization of α₂-plasmin inhibitor from human plasma. Journal of Biological Chemistry 251: 5956
• 55 Müllertz S, Clemmensen I. 1976; The primary inhibitor of plasmin in human plasma. Biochemical Journal 159: 545
• 56 Mürer EH. 1968; Release reaction and energy metabolism in blood platelets with special reference to the burst in oxygen uptake. Biochemica et biophysica acta 162: 320
• 57 Mürer EH. 1971; Compounds known to affect the cyclic adenosine monophosphate level in blood platelets. effect on thrombin-induced clot retraction and platelet release. Biochemica et biophysica acta 237: 310
• 58 Mürer EH. 1972; Factors influencing the initiation and the extrusion phase of the platelet release reaction. Biochemica et biophysica acta 261: 435
• 59 Mürer EH, Holme R. 1970; Study of the release of calcium from human blood platelets and its inhibition by metabolic inhibitors, N-ethylmaleimide and aspirin. Biochemica et Biophysica Acta 222: 197
• 60 Ohlsson K, Collen D. Comparison of the reaction of neutral granulocyte proteases with the major plasma protease inhibitors and with antiplasmin. Scandinavian Journal of Clinical and Laboratory Investigations. (in press)
• 61 Ratnoff OD, Colopy JE. 1955; A familiar hemorrhagic trait associated with deficiency of clot-promoting fraction of plasma. Journal of Clinical Investigations 34: 602
• 62 Reid WO, Silver MJ. 1964; Activation of the blood fibrinolytic enzyme system by platelets. American Journal of Physiology 206: 1255
• 63 Revak SD, Cochrane CG. 1976; The relationships of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate portions of the molecule. journal of Clinical Investigations 57: 852
• 64 Revak SD, Cochrane CG, Griffin JH. 1976; The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. Journal of Clinical Investigations 59: 1167
• 65 Robbins KC, Bernabe P, Arzadon L, Summaria L. 1972; The primary structure of human plasminogen. 1. The NH₂-terminal sequences of human plasminogen and the s-carboxymethyl heavy (A) and light (B) chain derivatives of plasmin. Journal of Biological Chemistry 247: 6757
• 66 Robbins KC, Summaria L, Delwyn N, Barlow GH. 1965; Further studies on the purification and characterization of human plasminogen and plasmin. Journal of Biology Chemistry 240: 541
• 67 Robbins KC, Summaria L, Hsieh B, Shah RJ. 1967; The peptide chains of human plasmin. Journal of Biological Chemistry 272: 2333
• 68 Saito H, Ratnoff OD, Donaldson VM. 1974; Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma. Circulation Research 39: 641
• 69 Saito H, Ratnoff OD, Waldmann R, Abraham JP. 1975; Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-medicated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability. Journal of Clinical Investigation 55: 1082
• 70 Schiffman S, Lee P. 1975; Partial purification and characterization of contact activation cofactor. Journal of Clinical Investigation 56: 1082
• 71 Schreiber AD, Austen KF. 1973; Interrelationships of the fibrinolytic, coagulation, kinin generating and complement systems. Series Haematologica 6: 593
• 72 Schreiber AD, Austen KF. 1974; Hageman factor-independent fibrinolytic pathway. Clinical Experimental Immunology 17: 587
• 73 Schreiber AD, Kaplan AP, Austen KF. 1973; Inhibition of CllNH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. Journal of Clinical Investigation 521: 1402
• 74 Sodetz JM, Brockway WJ, Mann KB, Castellino FJ. 1974; The mechanism of activation of rabbit plasminogen by urokinase. Lack of a preactivation peptide. Biochemical and Biophysical Research Communications 60: 729
• 75 Sodetz JM, Castellino FJ. 1975; The mechanism of activation of rabbit plasminogen by urokinase. Journal of Biological Chemistry 250: 2041
• 76 Summaria L, Argedon L, Bernabe P, Robbins KC. 1975; The activation of plasminogen by urokinase in the presence of the plasma inhibitor urokinase. Journal of Biological Chemistry 250: 3988
• 77 Summaria L, Hsieh B, Groskopf WR, Robbins KC, Barlow G. 1967; The isolation and characterization of the S-carboxymethyl B (light) chain derivative of human plasmin. Journal of Biological Chemistry 242: 5046
• 78 Taylor Jr FB, Müller-Eberhard HJ. 1970; Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets. Journal of Clinical Investigation 49: 2068
• 79 Taylor JR FB, Nilsson UR, Creech RH, Caroll ET, Beisswenger JG. 1973; a Coagulolysis. mechanism of formation and lysis of dilute whole blood clots and application of this assay into study of certain hypercoagulable states. Seminars in Haematology 6: 528
• 80 Taylor Jr FB, Nilsson UR, Creech RH, Carroll ET, Beisswenger JG. 1973. b A new approach to the study of hypercoagulability. a discussion of the mechanism and application of a coagulolysis assay which measures both coagulation and fibrinolytic activities. In: Thrombosis; Mechanisms and Control. F. K. Schattauer Verlag; Stuttgart-New York: 223-235
• 81 Tateishi I, Steiner M, Baldini MG. 1973; Studies on lipid peroxides in platelets. III. effect on physiologic platelet function. Journal of Laboratory and Clinical Medicine 81: 587
• 82 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide subtrate. Scandinavian Journal of Clinical and Laboratory Investigation. in press
• 83 Thompson RE, Mandlejr R, Kaplan AP. 1977; Interaction of factor XI and kallikrein with high molecular weight kininogen. Thrombosis and Haemostasis 38: 13 (Abst.)
• 84 Valdorf-Hansen JF, Zucker MB. 1971; Effect of temperature and inhibitors on serotonin – ¹⁴C release from human platelets. American Journal of Physiology 220: 105
• 85 Vennerod AM, Laake K. 1976; Prekallikrein and plasminogen proactivator. Absence of plasminogen proactivator in Fletcher factor deficient plasma. Thrombosis Research 8: 519
• 86 Verstraete M, Vermylen J, Schetz J. 1978; Biochemical changes noted during intermittent administration of streptokinase. Thrombosis and Haemostasis 39: 61
• 87 Violand BN, Castellino FJ. 1976; The mechanism of urokinase catalyzed activation of human plasminogen. Journal of Biological Chemistry 251: 3906
• 88 Wallen P, Wiman B. 1970; Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations. Biochimica et biophysica acta 221: 20
• 89 Walther PJ, Steinman HM, Hill RL, McKee PA. 1974; Activation of plasminogen by urokinase. Partial characterization of a preactivation peptide. Journal of Biological Chemistry 249: 1173
• 90 Walther PJ, Hill RL, McKee PA. 1975; The importance of the preactivation peptide in the two-stage mechanism of human plasminogen activation. Journal of Biological Chemistry 250: 5926
• 91 Weiss AS, Gallin JI, Kaplan AP. 1974; Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. Journal of Clinical Investigations 53: 622
• 92 White JG, Krumwiede M. 1973; Influence of cytochalasin B on the shape change induced in platelets by cold. Blood 41: 823
• 93 Wiman B. 1973; Primary structure of peptides released during activation of human plasminogen by urokinase. European Journal of Biochemistry 39: 1
• 94 Wiman B. 1977; Primary structure of the B chain of human plasmin. European Journal of Biochemistry 76: 129
• 95 Wiman B, Collen D. 1977; Purification and characterization of human antiplasmin, the fast acting plasmin inhibitor in plasma. European Journal of Biochemistry 78: 19
• 96 Wimen B, Wallen P. 1973; Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound. European Journal of Biochemistry 36: 25
• 97 Wu KK, Barnes RW, Hoak JC. 1976; Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis. Circulation 53: 687
• 98 Wu KK, Hoak JC. 1974; New method for the quantitative detection of platelet aggregates inpatients with arterial insufficiency. Lancet II: 924
• 99 Wuepper KD. 1973; Prekallikrein deficiency in man. Journal of Experimental Medicine 138: 1345
• 100 Wuepper KD, Miller DR, Lacombe MJ. 1975; Flaujeuc trait. Deficiency of human plasma kininogen. Journal of Clinical Investigation 56: 1663
• 101 Zucker MB, Borrelli J. 1960; Viscous metamorphosis produced by chilling and by clotting: failure to find specific defect of viscous metamorphosis in PTA syndrome. Thrombosis et Diathesis Haemorrhagica 4: 424